InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | 2026-04-28 | Raben David | Chief Medical Officer | Sale | 5,500 | $22.88 | $126K | 55.3K | View ↗ | |
| 2026-04-21 | 2026-04-22 | Hyep Ivan | Chief Financial Officer | Sale | 9,200 | $23.00 | $212K | 145.4K | View ↗ | |
| 2026-04-20 | 2026-04-20 | Mazumdar Claire | Director & Chief Executive Officer | Sale | 15.0K | $23.61 | $354K | 362.2K | View ↗ | |
| 2026-04-15 | 2026-04-17 | Cohlhepp Ryan | Director & President and COO | Sale | 12.5K | $23.01 | $288K | 196.1K | View ↗ | |
| 2026-03-25 | 2026-03-26 | Raben David | Chief Medical Officer | Sale | 5,500 | $18.95 | $104K | 55.3K | View ↗ |
| Metric | FY2024 | FY2023 |
|---|---|---|
| Research and development | $55.4M+159.2% | $21.4M |
| General and administrative | $18.8M+102.4% | $9.3M |
| Total operating expenses | $82.4M+106.5% | $39.9M |
| Loss from operations | -$82.4M-106.5% | -$39.9M |
| Interest income | $14.6M+1009.7% | $1.3M |
| Change in fair value of Series B preferred stock tranche rights liability | $0+100.0% | -$13.4M |
| Total other income (expense) | $14.6M+220.6% | -$12.1M |
| Net loss before income taxes | -$67.8M-30.5% | -$52.0M |
| Income tax expense | -$187K-3640.0% | -$5K |
| Net loss | -$68.0M-30.8% | -$52.0M |
| Net Loss per share, basic (in usd per share) | -$4K+95.5% | -$90K |
| Net Loss per share, diluted (in usd per share) | -$4K+95.5% | -$90K |
| Weighted-average number common shares outstanding, basic (in shares) | $16.81T+2797.0% | $580.11B |
| Weighted-average number common shares outstanding, diluted (in shares) | $16.81T+2797.0% | $580.11B |
| Related Party | ||
| Research and development | $55.4M+159.2% | $21.4M |
| Nonrelated Party | ||
| Research and development | $55.4M+159.2% | $21.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)